4 news items
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
ARVN
17 Jun 24
degradation research into meaningful clinical trials and impactful treatment; the potential therapeutic benefits of the product candidates in Arvinas
Walmart Posts Upbeat Earnings, Joins Canada Goose, Lightspeed Commerce And Other Big Stocks Moving Higher On Thursday
ARVN
ASTS
BA
16 May 24
. Sales were $161.51 billion, up 6.0% year over year or 5.8% (at constant currency), including a benefit of ~1% from an additional selling day, beating
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCEĀ®)
ARVN
PFE
16 May 24
of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
ARVN
NVS
7 May 24
) benefit
- Prev
- 1
- Next